New Phase 1 Results for ALN-APP Presented at Clinical Trials on Alzheimer’s Disease Conference

25 Oct, 2023 New Phase 1 Results for ALN-APP Presented at Clinical Trials on Alzheimer’s Disease Conference

We presented additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy, in a late-breaker session at the 16^th Clinical Trials on Alzheimer’s Disease conference.

Mummery, et al. “Phase 1 Safety, Tolerability, and Pharmacological Results of ALN-APP, the First Investigational RNA Interference Therapeutic in Development for Early-Onset Alzheimer’s Disease”